Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioNexus Gene Lab Corp. (BGLC : NSDQ)

• Company Description    BioNexus Gene Lab Corp. is an emerging company in the business of selling chemical raw materials principally in the Southeast Asia region and the development of biopsy tests for early diagnosis and personalized health management. BioNexus Gene Lab Corp. is based in KUALA LUMPUR, Malaysia. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $5.43 Daily Weekly Monthly 20 Day Moving Average: 38,328 shares Shares Outstanding: 1.80 (millions) Market Capitalization: $9.76 (millions) Beta: 5.31 52 Week High: $8.98 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.31% -0.47% 12 Week 85.32% 68.34% Year To Date 94.14% 37.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 28-A-28-7 TOWER A MENARA UOA BANGSAR N0.5 JLN BANSAR UTAMA 1 - KUALA LUMPUR,N8 59200 - ph: 1 307 241 6898 fax: - ir@bionexuslab.com http://www.bionexusgenelab.com

• General Corporate Information    Officers Su-Leng Tan Lee - Chief Executive Officer and Director Su-Leng Tan Lee - Acting Chief Financial Officer Chee Keong Yap - Director Jook Yuen Low - Director Muhammad Azrul bin Abdul Hamid - Director Peer Information BioNexus Gene Lab Corp. (CHCR) BioNexus Gene Lab Corp. (ESRX) BioNexus Gene Lab Corp. (MYDP) BioNexus Gene Lab Corp. (COR) BioNexus Gene Lab Corp. (GBCS) BioNexus Gene Lab Corp. (LAXAF) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Medical Services Sector: Medical CUSIP: 090628306 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/21/25 Share - Related Items Shares Outstanding: 1.80 Most Recent Split Date: 4.00 (0.10:1) Beta: 5.31 Market Capitalization: $9.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.30 Price/Cash Flow: - Price / Sales: 1.02 EPS Growth vs. Year Ago Period: -440.00% vs. Previous Quarter: -1,033.33% Sales Growth vs. Year Ago Period: 14.43% vs. Previous Quarter: 5.76% ROE 06/30/25 - -35.54 03/31/25 - -24.18 12/31/24 - -17.47 ROA 06/30/25 - -29.08 03/31/25 - -20.14 12/31/24 - -14.62 Current Ratio 06/30/25 - 3.63 03/31/25 - 4.19 12/31/24 - 3.81 Quick Ratio 06/30/25 - 2.94 03/31/25 - 3.44 12/31/24 - 3.10 Operating Margin 06/30/25 - -30.70 03/31/25 - -22.85 12/31/24 - -16.81 Net Margin 06/30/25 - -30.70 03/31/25 - -22.85 12/31/24 - -16.81 Pre-Tax Margin 06/30/25 - -31.47 03/31/25 - -23.03 12/31/24 - -16.77 Book Value 06/30/25 - 4.19 03/31/25 - 4.33 12/31/24 - 4.63 Inventory Turnover 06/30/25 - 6.34 03/31/25 - 6.41 12/31/24 - 6.73 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©